December 17, 2007 -- Showing that drug product safety concerns cut both ways, Chinese officials pulled more than 100,000 vials of a childhood vaccine manufactured by Merck (NYSE: MRK) from Chinese shelves. However, it may be better to import than to produce domestically, as China officials claimed that parents need not be worried because foreign-sourced drugs are subjected to regulatory scrutiny before they are allowed into China. That scrutiny did not stop China from removing the drug from further sales. More details...
